257 related articles for article (PubMed ID: 35186735)
1. Large Animal Models of Breast Cancer.
Mondal P; Bailey KL; Cartwright SB; Band V; Carlson MA
Front Oncol; 2022; 12():788038. PubMed ID: 35186735
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Transcriptional Regulatory Network Reprogramming by using the CRISPR/Cas9 System: An Oncogenetics Perspective.
Singh DD; Verma R; Tripathi SK; Sahu R; Trivedi P; Yadav DK
Curr Top Med Chem; 2021; 21(31):2800-2813. PubMed ID: 34477520
[TBL] [Abstract][Full Text] [Related]
3. Perspective: Humanized Pig Models of Bladder Cancer.
Segatto NV; Bender CB; Seixas FK; Schachtschneider K; Schook L; Robertson N; Qazi A; Carlino M; Jordan L; Bolt C; Collares T
Front Mol Biosci; 2021; 8():681044. PubMed ID: 34079821
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and Applications of Canine In Vitro Models of Bladder Cancer in Veterinary Medicine: An Up-to-Date Mini Review.
Nowak Ł; Krajewski W; Małkiewicz B; Szydełko T; Pawlak A
Animals (Basel); 2022 Feb; 12(4):. PubMed ID: 35203224
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and TP53 Gene-Mutations: Family Predisposition and Radioecological Risk of Developing Breast Cancer.
Apsalikov B; Manambaeva Z; Ospanov E; Massabayeva M; Zhabagin K; Zhagiparova Z; Maximov V; Voropaeva E; Apsalikov K; Belikhina T; Abdrahmanov R; Cherepkova E; Tanatarov S; Massadykov A; Urazalina N
Asian Pac J Cancer Prev; 2016; 17(8):4059-62. PubMed ID: 27644661
[TBL] [Abstract][Full Text] [Related]
6. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
[TBL] [Abstract][Full Text] [Related]
7. Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial.
Pohl-Rescigno E; Hauke J; Loibl S; Möbus V; Denkert C; Fasching PA; Kayali M; Ernst C; Weber-Lassalle N; Hanusch C; Tesch H; Müller V; Altmüller J; Thiele H; Untch M; Lübbe K; Nürnberg P; Rhiem K; Furlanetto J; Lederer B; Jackisch C; Nekljudova V; Schmutzler RK; Schneeweiss A; Hahnen E
JAMA Oncol; 2020 May; 6(5):744-748. PubMed ID: 32163106
[TBL] [Abstract][Full Text] [Related]
8. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
Sokolenko AP; Sokolova TN; Ni VI; Preobrazhenskaya EV; Iyevleva AG; Aleksakhina SN; Romanko AA; Bessonov AA; Gorodnova TV; Anisimova EI; Savonevich EL; Bizin IV; Stepanov IA; Krivorotko PV; Berlev IV; Belyaev AM; Togo AV; Imyanitov EN
Breast Cancer Res Treat; 2020 Nov; 184(1):229-235. PubMed ID: 32776218
[TBL] [Abstract][Full Text] [Related]
9. Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms.
Bernstein-Molho R; Singer A; Laitman Y; Netzer I; Zalmanoviz S; Friedman E
Breast Cancer Res Treat; 2019 Jul; 176(1):165-170. PubMed ID: 30980208
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
[TBL] [Abstract][Full Text] [Related]
12. CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.
Palanca Suela S; Esteban Cardeñosa E; Barragán González E; de Juan Jiménez I; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Montalar Salcedo J; Castel Sánchez V; Bolufer Gilabert P;
Breast Cancer Res Treat; 2010 Jan; 119(1):87-93. PubMed ID: 19214744
[TBL] [Abstract][Full Text] [Related]
13. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
Bonadona V; Sinilnikova OM; Chopin S; Antoniou AC; Mignotte H; Mathevet P; Brémond A; Martin A; Bobin JY; Romestaing P; Raudrant D; Rudigoz RC; Léoné M; Chauvin F; Easton DF; Lenoir GM; Lasset C
Genes Chromosomes Cancer; 2005 Aug; 43(4):404-13. PubMed ID: 15887246
[TBL] [Abstract][Full Text] [Related]
14. HER2-positive breast cancer in a germline
Uchida N; Takeshita M; Suda T; Matsui Y; Yoshida M
Int Cancer Conf J; 2021 Jul; 10(3):181-185. PubMed ID: 34221828
[TBL] [Abstract][Full Text] [Related]
15. Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer.
Sim EJ; Ko KP; Ahn C; Park SM; Surh YJ; An S; Kim SW; Lee MH; Lee JW; Lee JE; Kim KS; Yom CK; Kim HA; Park SK
Breast Cancer Res Treat; 2020 Nov; 184(2):615-626. PubMed ID: 33068197
[TBL] [Abstract][Full Text] [Related]
16. Current Status of Breast Organoid Models.
Mohan SC; Lee TY; Giuliano AE; Cui X
Front Bioeng Biotechnol; 2021; 9():745943. PubMed ID: 34805107
[TBL] [Abstract][Full Text] [Related]
17. Mammographic density and breast cancer in women from high risk families.
Ramón Y Cajal T; Chirivella I; Miranda J; Teule A; Izquierdo Á; Balmaña J; Sánchez-Heras AB; Llort G; Fisas D; Lope V; Hernández-Agudo E; Juan-Fita MJ; Tena I; Robles L; Guillén-Ponce C; Pérez-Segura P; Luque-Molina MS; Hernando-Polo S; Salinas M; Brunet J; Salas-Trejo MD; Barnadas A; Pollán M
Breast Cancer Res; 2015 Jul; 17(1):93. PubMed ID: 26163143
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
Jackson SA; Davis AA; Li J; Yi N; McCormick SR; Grant C; Fallen T; Crawford B; Loranger K; Litton J; Arun B; Vande Wydeven K; Sidani A; Farmer K; Sanders M; Hoskins K; Nussbaum R; Esserman L; Garber JE; Kaklamani VG;
Cancer; 2014 May; 120(10):1557-64. PubMed ID: 24522996
[TBL] [Abstract][Full Text] [Related]
19. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
[TBL] [Abstract][Full Text] [Related]
20. Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients.
Paixão D; Torrezan GT; Santiago KM; Formiga MN; Ahuno ST; Dias-Neto E; Tojal da Silva I; Foulkes WD; Polak P; Carraro DM
Front Oncol; 2022; 12():976959. PubMed ID: 36119527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
